JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casimiro, D. R.
Right arrow Articles by Shiver, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casimiro, D. R.
Right arrow Articles by Shiver, J. W.
Journal of Virology, June 2003, p. 6305-6313, Vol. 77, No. 11
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.11.6305-6313.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

Danilo R. Casimiro,1* Ling Chen,1 Tong-Ming Fu,1 Robert K. Evans,2 Michael J. Caulfield,3 Mary-Ellen Davies,1 Aimin Tang,1 Minchun Chen,1 Lingyi Huang,1 Virginia Harris,1 Daniel C. Freed,1 Keith A. Wilson,1 Sheri Dubey,1 De-Min Zhu,2 Denise Nawrocki,2 Henryk Mach,2 Robert Troutman,2 Lynne Isopi,2 Donna Williams,2 William Hurni,3 Zheng Xu,1 Jeffrey G. Smith,3 Su Wang,3 Xu Liu,3 Liming Guan,1 Romnie Long,1 Wendy Trigona,1 Gwendolyn J. Heidecker,1 Helen C. Perry,1 Natasha Persaud,1 Timothy J. Toner,1 Qin Su,1 Xiaoping Liang,1 Rima Youil,1 Michael Chastain,1 Andrew J. Bett,1 David B. Volkin,1 Emilio A. Emini,1 and John W. Shiver1

Departments of Viral Vaccine Research,1 Vaccine Pharmaceutical Research and Development,2 Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 194863

Received 21 October 2002/ Accepted 7 March 2003

Cellular immune responses, particularly those associated with CD3+ CD8+ cytotoxic T lymphocytes (CTL), play a primary role in controlling viral infection, including persistent infection with human immunodeficiency virus type 1 (HIV-1). Accordingly, recent HIV-1 vaccine research efforts have focused on establishing the optimal means of eliciting such antiviral CTL immune responses. We evaluated several DNA vaccine formulations, a modified vaccinia virus Ankara vector, and a replication-defective adenovirus serotype 5 (Ad5) vector, each expressing the same codon-optimized HIV-1 gag gene for immunogenicity in rhesus monkeys. The DNA vaccines were formulated with and without one of two chemical adjuvants (aluminum phosphate and CRL1005). The Ad5-gag vector was the most effective in eliciting anti-Gag CTL. The vaccine produced both CD4+ and CD8+ T-cell responses, with the latter consistently being the dominant component. To determine the effect of existing antiadenovirus immunity on Ad5-gag-induced immune responses, monkeys were exposed to adenovirus subtype 5 that did not encode antigen prior to immunization with Ad5-gag. The resulting anti-Gag T-cell responses were attenuated but not abolished. Regimens that involved priming with different DNA vaccine formulations followed by boosting with the adenovirus vector were also compared. Of the formulations tested, the DNA-CRL1005 vaccine primed T-cell responses most effectively and provided the best overall immune responses after boosting with Ad5-gag. These results are suggestive of an immunization strategy for humans that are centered on use of the adenovirus vector and in which existing adenovirus immunity may be overcome by combined immunization with adjuvanted DNA and adenovirus vector boosting.


* Corresponding author. Mailing address: Department of Viral Vaccine Research, Merck & Co., WP26-145, 770 Sumneytown Pike, West Point, PA 19486. Phone: (215) 652-3129. Fax: (215) 652-7320. E-mail: danilo_casimiro{at}merck.com.


Journal of Virology, June 2003, p. 6305-6313, Vol. 77, No. 11
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.11.6305-6313.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.